ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Remote-Controllable Immune-Priming Spot Formation Via Nanocomplexed Hydrogel-Assisted Histotripsy: Immunoasis.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Immunotherapy, which harnesses the immune system to eliminate cancer cells, offers durable, and specific responses. However, many tumors exhibit "immune deserts" - immunosuppressive microenvironments with low T cell infiltration due to the dominance of suppressive myeloid cells and limited inflammatory cues. Cancer vaccines combining tumor antigens and adjuvants can potentially convert these immune deserts into immune-active lesions. Yet, systemic administration often leads to adverse effects such as cytokine storms and off-target immune activation. To address this, we propose "Immunoasis", a spatiotemporally controllable immunotherapeutic system. This platform integrates injectable, adjuvant-loaded hydrogels with externally triggered boiling histotripsy. The hydrogel enables prolonged local retention of immunostimulatory payloads, while histotripsy disrupts tumor tissues and induces in situ conversion of the gel into nanocomplexes enriched with antigens and adjuvants. This localized activation enhances antigen presentation and promotes T cell recruitment at the tumor site. The tunable nature of the ultrasound stimulus provides flexible treatment scheduling and supports personalized cancer therapy. By establishing immune-priming niches within the tumor, Immunoasis effectively transforms immune deserts into immune-responsive microenvironments, enhancing antitumor immunity and improving therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.